H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $22.00 price target on Unicycive Therapeutics (NASDAQ: UNCY).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments